Matching articles for "Penbraya"

Penmenvy — A Second Pentavalent Meningococcal Vaccine

   
The Medical Letter on Drugs and Therapeutics • April 14, 2025;  (Issue 1726)
The FDA has licensed the pentavalent vaccine Penmenvy (GSK) for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, B, C, W, or Y (MenABCWY) in persons 10-25 years...
The FDA has licensed the pentavalent vaccine Penmenvy (GSK) for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, B, C, W, or Y (MenABCWY) in persons 10-25 years old. Penmenvy is the second pentavalent meningococcal vaccine to become available in the US; Penbraya was licensed in 2023.
Med Lett Drugs Ther. 2025 Apr 14;67(1726):57-9 | Show Full IntroductionHide Full Introduction

Penbraya: A Pentavalent Meningococcal Vaccine

   
The Medical Letter on Drugs and Therapeutics • March 18, 2024;  (Issue 1698)
The FDA has licensed Penbraya (Pfizer), a pentavalent polysaccharide conjugate meningococcal vaccine, for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, B, C, W,...
The FDA has licensed Penbraya (Pfizer), a pentavalent polysaccharide conjugate meningococcal vaccine, for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, B, C, W, or Y (MenABCWY) in persons 10-25 years old. Penbraya is the only meningococcal vaccine that contains all five of these serogroups. Two quadrivalent polysaccharide conjugate meningococcal vaccines containing serogroups A, C, W, and Y (MenACWY; Menveo, MenQuadfi) and two meningococcal serogroup B vaccines (MenB; Bexsero, Trumenba) are available in the US (see Table 2).
Med Lett Drugs Ther. 2024 Mar 18;66(1698):43-5 | Show Full IntroductionHide Full Introduction